Correction to Brigatinib in Japanese patients with ALK-positive non-small-cell lung cancer: Final results of the phase 2 J-ALTA trial. . Cancer Sci 2023 Dec 10. doi: 10.1111/cas.16000.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

. Correction to Brigatinib in Japanese patients with ALK-positive non-small-cell lung cancer: Final results of the phase 2 J-ALTA trial. Cancer Sci 2023 Dec 10. doi: 10.1111/cas.16000.
PMID: 38073184